Cargando…

Urinary hsv2-miR-H9 to hsa-miR-3659 ratio is an effective marker for discriminating prostate cancer from benign prostate hyperplasia in patients within the prostate-specific antigen grey zone

PURPOSE: Tumor microRNAs (miRNAs) are released to biofluids directly or indirectly. Although urinary miRNAs are promising non-invasive biomarkers for the diagnosis of prostate cancer (PCa), their clinical application is challenging for technical reasons. We examined the efficacy of urinary hsv2-miR-...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Ho Won, Byun, Young Joon, Moon, Sung Min, Kim, Kyeong, Piao, Xuan-Mei, Zheng, Chuang-Ming, Moon, Sung-Kwon, Choi, Yung Hyun, Kim, Won Tae, Kim, Yong-June, Lee, Sang-Cheol, Yun, Seok Joong, Kim, Wun-Jae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Urological Association 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902421/
https://www.ncbi.nlm.nih.gov/pubmed/35244999
http://dx.doi.org/10.4111/icu.20210493
_version_ 1784664597220818944
author Kang, Ho Won
Byun, Young Joon
Moon, Sung Min
Kim, Kyeong
Piao, Xuan-Mei
Zheng, Chuang-Ming
Moon, Sung-Kwon
Choi, Yung Hyun
Kim, Won Tae
Kim, Yong-June
Lee, Sang-Cheol
Yun, Seok Joong
Kim, Wun-Jae
author_facet Kang, Ho Won
Byun, Young Joon
Moon, Sung Min
Kim, Kyeong
Piao, Xuan-Mei
Zheng, Chuang-Ming
Moon, Sung-Kwon
Choi, Yung Hyun
Kim, Won Tae
Kim, Yong-June
Lee, Sang-Cheol
Yun, Seok Joong
Kim, Wun-Jae
author_sort Kang, Ho Won
collection PubMed
description PURPOSE: Tumor microRNAs (miRNAs) are released to biofluids directly or indirectly. Although urinary miRNAs are promising non-invasive biomarkers for the diagnosis of prostate cancer (PCa), their clinical application is challenging for technical reasons. We examined the efficacy of urinary hsv2-miR-H9 to hsa-miR-3659 ratio as a non-invasive diagnostic biomarker of PCa. MATERIALS AND METHODS: The expression of urinary miRNAs was quantified by real-time PCR in 116 samples from 53 patients with benign prostatic hyperplasia (BPH) and 63 patients with PCa. The miRNA expression ratio was calculated using an upregulated miRNA (hsv2-miR-H9) as the numerator and a downregulated miRNA (hsa-miR-3659) as the denominator. RESULTS: The urinary miR-H9 to miR-3659 ratio was significantly higher in PCa than in BPH controls (p<0.001). The diagnostic accuracy of the urinary miRNA expression ratio was comparable with that of prostate-specific antigen (PSA) (receiver operating characteristic [ROC] curve comparison, p=0.287). The area under the curve for urinary miRNA expression ratio was 0.862 and that for PSA was 0.642 in the “PSA gray zone” (3–10 ng/mL) (ROC curve comparison, p=0.034). The use of the urinary miRNA expression ratio would have prevented 70.6% of unnecessary prostate biopsies; however, 28.6% of PCa cases could be missed in patients within the PSA gray zone. CONCLUSIONS: The expression ratio of urinary miR-H9 to miR-3659 could be a relevant non-invasive biomarker for PCa diagnosis, particularly for patients within the PSA gray zone.
format Online
Article
Text
id pubmed-8902421
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Korean Urological Association
record_format MEDLINE/PubMed
spelling pubmed-89024212022-03-16 Urinary hsv2-miR-H9 to hsa-miR-3659 ratio is an effective marker for discriminating prostate cancer from benign prostate hyperplasia in patients within the prostate-specific antigen grey zone Kang, Ho Won Byun, Young Joon Moon, Sung Min Kim, Kyeong Piao, Xuan-Mei Zheng, Chuang-Ming Moon, Sung-Kwon Choi, Yung Hyun Kim, Won Tae Kim, Yong-June Lee, Sang-Cheol Yun, Seok Joong Kim, Wun-Jae Investig Clin Urol Original Article PURPOSE: Tumor microRNAs (miRNAs) are released to biofluids directly or indirectly. Although urinary miRNAs are promising non-invasive biomarkers for the diagnosis of prostate cancer (PCa), their clinical application is challenging for technical reasons. We examined the efficacy of urinary hsv2-miR-H9 to hsa-miR-3659 ratio as a non-invasive diagnostic biomarker of PCa. MATERIALS AND METHODS: The expression of urinary miRNAs was quantified by real-time PCR in 116 samples from 53 patients with benign prostatic hyperplasia (BPH) and 63 patients with PCa. The miRNA expression ratio was calculated using an upregulated miRNA (hsv2-miR-H9) as the numerator and a downregulated miRNA (hsa-miR-3659) as the denominator. RESULTS: The urinary miR-H9 to miR-3659 ratio was significantly higher in PCa than in BPH controls (p<0.001). The diagnostic accuracy of the urinary miRNA expression ratio was comparable with that of prostate-specific antigen (PSA) (receiver operating characteristic [ROC] curve comparison, p=0.287). The area under the curve for urinary miRNA expression ratio was 0.862 and that for PSA was 0.642 in the “PSA gray zone” (3–10 ng/mL) (ROC curve comparison, p=0.034). The use of the urinary miRNA expression ratio would have prevented 70.6% of unnecessary prostate biopsies; however, 28.6% of PCa cases could be missed in patients within the PSA gray zone. CONCLUSIONS: The expression ratio of urinary miR-H9 to miR-3659 could be a relevant non-invasive biomarker for PCa diagnosis, particularly for patients within the PSA gray zone. The Korean Urological Association 2022-03 2022-02-24 /pmc/articles/PMC8902421/ /pubmed/35244999 http://dx.doi.org/10.4111/icu.20210493 Text en © The Korean Urological Association https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Kang, Ho Won
Byun, Young Joon
Moon, Sung Min
Kim, Kyeong
Piao, Xuan-Mei
Zheng, Chuang-Ming
Moon, Sung-Kwon
Choi, Yung Hyun
Kim, Won Tae
Kim, Yong-June
Lee, Sang-Cheol
Yun, Seok Joong
Kim, Wun-Jae
Urinary hsv2-miR-H9 to hsa-miR-3659 ratio is an effective marker for discriminating prostate cancer from benign prostate hyperplasia in patients within the prostate-specific antigen grey zone
title Urinary hsv2-miR-H9 to hsa-miR-3659 ratio is an effective marker for discriminating prostate cancer from benign prostate hyperplasia in patients within the prostate-specific antigen grey zone
title_full Urinary hsv2-miR-H9 to hsa-miR-3659 ratio is an effective marker for discriminating prostate cancer from benign prostate hyperplasia in patients within the prostate-specific antigen grey zone
title_fullStr Urinary hsv2-miR-H9 to hsa-miR-3659 ratio is an effective marker for discriminating prostate cancer from benign prostate hyperplasia in patients within the prostate-specific antigen grey zone
title_full_unstemmed Urinary hsv2-miR-H9 to hsa-miR-3659 ratio is an effective marker for discriminating prostate cancer from benign prostate hyperplasia in patients within the prostate-specific antigen grey zone
title_short Urinary hsv2-miR-H9 to hsa-miR-3659 ratio is an effective marker for discriminating prostate cancer from benign prostate hyperplasia in patients within the prostate-specific antigen grey zone
title_sort urinary hsv2-mir-h9 to hsa-mir-3659 ratio is an effective marker for discriminating prostate cancer from benign prostate hyperplasia in patients within the prostate-specific antigen grey zone
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902421/
https://www.ncbi.nlm.nih.gov/pubmed/35244999
http://dx.doi.org/10.4111/icu.20210493
work_keys_str_mv AT kanghowon urinaryhsv2mirh9tohsamir3659ratioisaneffectivemarkerfordiscriminatingprostatecancerfrombenignprostatehyperplasiainpatientswithintheprostatespecificantigengreyzone
AT byunyoungjoon urinaryhsv2mirh9tohsamir3659ratioisaneffectivemarkerfordiscriminatingprostatecancerfrombenignprostatehyperplasiainpatientswithintheprostatespecificantigengreyzone
AT moonsungmin urinaryhsv2mirh9tohsamir3659ratioisaneffectivemarkerfordiscriminatingprostatecancerfrombenignprostatehyperplasiainpatientswithintheprostatespecificantigengreyzone
AT kimkyeong urinaryhsv2mirh9tohsamir3659ratioisaneffectivemarkerfordiscriminatingprostatecancerfrombenignprostatehyperplasiainpatientswithintheprostatespecificantigengreyzone
AT piaoxuanmei urinaryhsv2mirh9tohsamir3659ratioisaneffectivemarkerfordiscriminatingprostatecancerfrombenignprostatehyperplasiainpatientswithintheprostatespecificantigengreyzone
AT zhengchuangming urinaryhsv2mirh9tohsamir3659ratioisaneffectivemarkerfordiscriminatingprostatecancerfrombenignprostatehyperplasiainpatientswithintheprostatespecificantigengreyzone
AT moonsungkwon urinaryhsv2mirh9tohsamir3659ratioisaneffectivemarkerfordiscriminatingprostatecancerfrombenignprostatehyperplasiainpatientswithintheprostatespecificantigengreyzone
AT choiyunghyun urinaryhsv2mirh9tohsamir3659ratioisaneffectivemarkerfordiscriminatingprostatecancerfrombenignprostatehyperplasiainpatientswithintheprostatespecificantigengreyzone
AT kimwontae urinaryhsv2mirh9tohsamir3659ratioisaneffectivemarkerfordiscriminatingprostatecancerfrombenignprostatehyperplasiainpatientswithintheprostatespecificantigengreyzone
AT kimyongjune urinaryhsv2mirh9tohsamir3659ratioisaneffectivemarkerfordiscriminatingprostatecancerfrombenignprostatehyperplasiainpatientswithintheprostatespecificantigengreyzone
AT leesangcheol urinaryhsv2mirh9tohsamir3659ratioisaneffectivemarkerfordiscriminatingprostatecancerfrombenignprostatehyperplasiainpatientswithintheprostatespecificantigengreyzone
AT yunseokjoong urinaryhsv2mirh9tohsamir3659ratioisaneffectivemarkerfordiscriminatingprostatecancerfrombenignprostatehyperplasiainpatientswithintheprostatespecificantigengreyzone
AT kimwunjae urinaryhsv2mirh9tohsamir3659ratioisaneffectivemarkerfordiscriminatingprostatecancerfrombenignprostatehyperplasiainpatientswithintheprostatespecificantigengreyzone